| 摘要 |
This invention provides methods for determining liposome bioequivalence between a generic drug product and a reference brand-name product. Specific methods for determining bioequivalence between doxorubicin hydrochloric acid (HCl) liposome injection product (Doxil®) and a generic pegylated liposome doxorubicin product are disclosed herein.
|
